Loading
A phase 1/2 trial of GSK4418959 in colorectal cancer and endometrial cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06710847 by GlaxoSmithKline, with 14 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-06-22. Interventions recorded: GSK4418959 and PD-1 inhibitor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer and the tag pipeline.
Shares GSK, Endometrial cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer and the tag pipeline.
Shares GSK, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/